Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;7(7 Suppl SC2S5-S22):S5-S22.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting

Neal Bhatia  1 , Andrew Blauvelt  2 , Marc Brown  3 , Whitney High  4 , Craig T Leonardi  5 , Ted Rosen  6 , Linda Stein Gold  7 , Eggert Stockfleth  8 , Bruce Strober  9 , Neil A Swanson  10 , George Martin  11
Affiliations

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting

Neal Bhatia et al. J Clin Aesthet Dermatol. 2014 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Targets in biologic drug development. Note that both secukinumab and ixekizumab block IL-17A while brodalumab blocks IL-17RA.
Figure 2
Figure 2
Cytokines and cytokine inhibitors in chronic inflammation
Figure 3
Figure 3
Function of the Th17 effector cytokines
Figure 4
Figure 4
Ustekinumab Phase 3 PASI response over 28 weeks
Figure 5
Figure 5
Apremilast Phase 3 (ESTEEM 1): PASI-75 by prior treatment experience at Week 16
Figure 6
Figure 6
Apremilast Phase 3 (ESTEEM 1): Select secondary endpoints
Figure 7
Figure 7
In the absence of the hedgehog ligand, PTCH inhibits SMO and the hedgehog signaling pathway is suppressed.
Figure 8
Figure 8
Hedgehog signaling pathway overview; target gene expression is initiated by hedgehog ligand binding to patch.
Figures 9A and 9B
Figures 9A and 9B
Inactivating mutations of PTCH prevent inhibition of SMO leading to constitutive activation of the hedgehog signaling pathway. This leads to tumor proliferation and survival.
Figures 9A and 9B
Figures 9A and 9B
Inactivating mutations of PTCH prevent inhibition of SMO leading to constitutive activation of the hedgehog signaling pathway. This leads to tumor proliferation and survival.
Figure 10
Figure 10
Tumor regression in the two cohorts (metastatic vs. locally advanced BCC) in the ERIVANCE study
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother. 2009;43(9):1456–1465. - PubMed
    1. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–657. - PMC - PubMed
    1. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab1 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190. - PubMed
    1. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Thl7 cytokines. Curr Rheumatol Rep. 2007;9(6):461–467. - PMC - PubMed
    1. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008;371(9625):1665–1674. - PubMed

LinkOut - more resources